CN113144006B - Traditional Chinese medicine composition for treating endometritis of female animals and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating endometritis of female animals and preparation method and application thereof Download PDFInfo
- Publication number
- CN113144006B CN113144006B CN202110458793.1A CN202110458793A CN113144006B CN 113144006 B CN113144006 B CN 113144006B CN 202110458793 A CN202110458793 A CN 202110458793A CN 113144006 B CN113144006 B CN 113144006B
- Authority
- CN
- China
- Prior art keywords
- extract
- macleaya cordata
- motherwort
- traditional chinese
- endometritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 208000004145 Endometritis Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 241001465754 Metazoa Species 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 56
- 240000007849 Macleaya cordata Species 0.000 claims abstract description 52
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims abstract description 42
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 26
- 241000207925 Leonurus Species 0.000 claims abstract description 26
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 26
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940084560 sanguinarine Drugs 0.000 claims abstract description 21
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000001556 precipitation Methods 0.000 claims description 17
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- DUNMULOWUUIQIL-RGMNGODLSA-N (2s)-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid;chloride Chemical compound Cl.C[N+]1(C)CCC[C@H]1C([O-])=O DUNMULOWUUIQIL-RGMNGODLSA-N 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000006184 cosolvent Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 27
- 210000004291 uterus Anatomy 0.000 description 25
- 239000000463 material Substances 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 210000003905 vulva Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 210000001215 vagina Anatomy 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical group C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000004100 Oxytetracycline Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 229960000625 oxytetracycline Drugs 0.000 description 3
- 235000019366 oxytetracycline Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CUJMCPPBTUATEJ-UHFFFAOYSA-N 1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)ethanone Chemical compound C1=CC=C2[N+](=O)C(C(=O)C)=C(C)N([O-])C2=C1 CUJMCPPBTUATEJ-UHFFFAOYSA-N 0.000 description 1
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 description 1
- 241000288784 Barleria cristata Species 0.000 description 1
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 240000001398 Typha domingensis Species 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- HYBRYAPKQCZIAE-UHFFFAOYSA-N allocryptopine Chemical compound C1=C2CCN(C)CC3=C(OC)C(OC)=CC=C3CC(=O)C2=CC2=C1OCO2 HYBRYAPKQCZIAE-UHFFFAOYSA-N 0.000 description 1
- NGFLTEGALWMQIJ-UHFFFAOYSA-N allocryptopine Natural products COc1ccc2CC(=O)c3cc4OCOc4cc3CN(C)CCc2c1OC NGFLTEGALWMQIJ-UHFFFAOYSA-N 0.000 description 1
- HUIJAZQRYSCNED-UHFFFAOYSA-N alpha-allo-cryptopine Natural products C1CN(C)CC2=C(OC)C(OC)=CC=C2CC(=O)C2=CC(OC)=C(OC)C=C21 HUIJAZQRYSCNED-UHFFFAOYSA-N 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960004055 ciprofloxacin lactate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020696 epimedium extract Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating female animal endometritis and a preparation method and application thereof, the composition comprises 60-90 parts of macleaya cordata and 10-40 parts of motherwort, the macleaya cordata and the motherwort are extracted to respectively prepare macleaya cordata extract and motherwort extract, and the content of sanguinarine in the macleaya cordata extract is not lower than 40% by mass. According to the invention, the macleaya cordata and the motherwort are adopted for compatibility application, the macleaya cordata is taken as a monarch drug, the motherwort is taken as a ministerial drug, the macleaya cordata extract and the motherwort extract are respectively taken as active ingredients, and the composition is used in a combined manner to play the effects of clearing heat and removing toxicity, and promoting blood circulation to remove blood stasis so as to treat endometritis of female animals.
Description
Technical Field
The invention belongs to the technical field of veterinary medicines, and particularly relates to a traditional Chinese medicine composition for treating endometritis of female animals, and a preparation method and application thereof.
Background
Endometritis in dams is the most common disease of the reproductive system during the animal breeding process, especially in breeding farms. More common cows and sows in the dam, if poorly maintained and managed, may have nearly half of the total number of dams with endometritis. At present, the treatment means mainly depend on local administration of the uterus by antibiotics or oral systemic administration. Compared with the traditional Chinese medicine preparation, the antibiotics for treating endometritis have the defects of easy generation of drug resistance, environmental pollution and single action mode. The traditional Chinese medicine uterus injectant is more at present, but the formula and the effective substances are too complex, so that the control of the product quality and the product effect is not facilitated.
Chinese patent CN103223021A discloses a uterus perfusion medicine for treating endometritis of cow and pig, which is composed of active ingredients of natural medicinal materials. The uterus perfusion medicine for preventing and treating the endometritis of the dairy cow and the sow is an active component of the medicinal material macleaya cordata, or the active components of cattail pollen and philippine violet herb are added into the uterus perfusion medicine. The medicinal materials of the invention are as follows: the herba violae has the effects of clearing away heat and toxic materials, cooling blood and relieving swelling, and is helpful for eliminating the uterine inflammation and swelling of sick female animals. The pollen Typhae can excite uterus, promote uterine contraction, facilitate discharge of pus in uterus, promote recovery of uterus function of sick female animals, and facilitate early pregnancy of female animals. Although the macleaya cordata extract is utilized in the comparison document, the content of sanguinarine in the macleaya cordata extract is not limited, the macleaya cordata extract is prepared by a decoction method, ethanol extraction is carried out on decoction liquid, the ethanol is recovered, and then the pH value is adjusted to prepare perfusion liquid medicine, but the sanguinarine is difficult to extract by the method.
Chinese patent CN102000145A discloses a compound perfusate of Chinese and western medicines for preventing and treating endometritis of female animals and a preparation method thereof, wherein the contents of the components are as follows: 0.5-5 g/L of safflower extract, 1-10 g/L of epimedium extract, 1-10 g/L of motherwort extract, 5-50 g/L of mequindox, 10-100 g/L of salicylic acid, 4-40 g/L of ciprofloxacin lactate, 3-30 g/L of metronidazole, 1-10 g/L of borneol, 20-40 g/L of polyvinylpyrrolidone, 100-200 g/L of ethanol, 805-15 g/L of tween-805 and the balance of water for injection. The invention overcomes the defects of large treatment dosage, high administration intensity, slow effect, long treatment course of pure traditional Chinese medicines, large treatment side effect and easy generation of resistance of pure western medicines by effectively combining the traditional Chinese medicines and the western medicines. Realizes the organic combination of treating both principal and secondary aspect of disease, antibiotic antibiosis and antiphlogosis and the uterus function restoration by the traditional Chinese medicine components. The contrast file uses the Chinese and western medicine combined perfusion agent to treat diseases such as bacterial endometritis, and the added antibiotics are easy to generate drug resistance, generate environmental pollution and have single action mode.
In the research process, sanguinarine is unstable in an aqueous solution with the pH value of 5.5-7.0, only 10% -20% of sanguinarine is basically left after the sanguinarine is placed for 1-3 months, macleaya cordata extract is extracted from a comparison document, and the final preparation form is directly prepared into uterine perfusion fluid, so that the stable storage of sanguinarine in macleaya cordata is not facilitated.
Disclosure of Invention
In order to overcome the problems in the prior art, the invention provides a traditional Chinese medicine composition for treating endometritis of female animals as well as a preparation method and application thereof.
In order to achieve the purpose, the invention is realized by the following technical scheme:
the invention provides a traditional Chinese medicine composition for treating female animal endometritis, which comprises the following raw materials in parts by weight: 60-90 parts of macleaya cordata and 10-40 parts of motherwort herb, wherein the macleaya cordata and the motherwort herb are respectively extracted to prepare a macleaya cordata extract and a motherwort herb extract, and the sanguinarine content in the macleaya cordata extract is not lower than 40% by mass.
In a preferred embodiment, the content of stachydrine hydrochloride in the motherwort herb extract is not less than 3% by mass.
In a preferred embodiment, the macleaya cordata extract is isolated from the extraction of macleaya cordata fruit pods.
In a preferred embodiment, the traditional Chinese medicine composition further comprises a pH regulator and a cosolvent, wherein the pH regulator is 1.08-1.65 parts, and the cosolvent is 0.32-0.33 part.
In a preferred embodiment, the product form of the Chinese medicinal composition is solid. Avoids the loss caused by unstable sanguinarine in the macleaya cordata extract in a solution state.
In a preferred embodiment, the traditional Chinese medicine composition is prepared into a perfusion agent by using water or normal saline when in use, and the pH value of the perfusion agent is 5.5-7.0.
The second aspect of the invention provides a preparation method of a traditional Chinese medicine composition for treating female animal endometritis, which comprises the following steps:
s1, taking 60-90 parts of macleaya cordata fruit pods, percolating and extracting with a dilute acid solution, then adding an alkali liquor, filtering to obtain a precipitate A, drying the precipitate A, extracting with an alcohol solution, then adding an acid solution to obtain a precipitate B, and drying the precipitate B to obtain a macleaya cordata extract;
s2, taking 10-40 parts of motherwort, extracting with water, concentrating the water extract, adding an alcohol solution for precipitation, recovering the alcohol solution, and drying to obtain a motherwort extract;
s3, mixing the macleaya cordata extract prepared in the step S1 and the motherwort herb extract prepared in the step S2, adding a pH regulator and a cosolvent, and sterilizing to obtain the extract;
the sanguinarine content in the macleaya cordata extract is not lower than 40% by mass, and the stachydrine hydrochloride content in the motherwort herb extract is not lower than 3% by mass.
In a preferred embodiment, the dilute acid solution is dilute sulfuric acid, the alkaline solution is sodium hydroxide solution, and the alcoholic solution is ethanol solution.
In a preferred embodiment, the traditional Chinese medicine composition is prepared into a perfusion agent by using water or normal saline when in use, and the pH value of the perfusion agent is 5.5-7.0.
The third aspect of the invention provides application of a traditional Chinese medicine composition for treating endometritis of female animals in preparation of a medicine for treating endometritis of female animals.
Macleaya cordata: is pungent and bitter in flavor and warm in nature, and can dispel wind, detoxify, dissipate blood stasis, relieve swelling and kill parasites. Mainly contains alkaloids such as sanguinarine, chelerythrine, protopine and allocryptopine, and has antibacterial, insecticidal, chewing-killing, liver function improving, immunity enhancing and anti-tumor effects.
Motherwort: being pungent and bitter in flavor and cold in nature, it can activate blood and resolve stasis, regulate menstruation and eliminate water. Mainly contains alkaloids such as stachydrine, leonurine and the like, and the modern pharmacological research shows that the traditional Chinese medicine composition has pharmacological effects on resisting platelet aggregation, reducing blood viscosity, protecting kidney, regulating menstruation, stopping bleeding, resisting inflammation, relieving pain, regulating immunity and the like; especially has strong uterine activity, can increase the frequency of uterine movement and promote uterine contraction.
The invention has the following beneficial effects:
(1) the invention provides a traditional Chinese medicine composition for treating endometritis of female animals, which is prepared by adopting macleaya cordata and motherwort for compatibility application, taking macleaya cordata as a monarch drug and motherwort as a ministerial drug, and respectively utilizing macleaya cordata extract and motherwort extract as active ingredients, wherein the mass percentage content of sanguinarine in the macleaya cordata extract is not less than 40%, and the composition has the effects of clearing heat and removing toxicity, and promoting blood circulation to remove blood stasis to treat the endometritis of the female animals.
(2) The macleaya cordata extract is prepared from macleaya cordata fruit pods, the macleaya cordata extract is heated and extracted by using a dilute acid solution, then alkali liquor is added, precipitation is obtained by filtering, the precipitation is dried, then the obtained product is extracted by using an alcohol solution, and then acid solution is added to obtain the precipitation, so that the sanguinarine content of the macleaya cordata extract is more than 40%, and the extraction rate is high. The obtained product is prepared into a solid mixture, so that the problem that sanguinarine is unstable in an aqueous solution with the pH value of 5.5-7.0 and only 10% -20% of sanguinarine is basically left after the sanguinarine is placed for 1-3 months is solved, and the stability of effective components is kept.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
In the description herein, reference to the description of the terms "one embodiment," "some embodiments," "an illustrative embodiment," "an example," "a specific example," or "some examples" or the like means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present disclosure. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Preparation of traditional Chinese medicine composition for treating endometritis of female animals
Example 1
(1) 6kg of macleaya cordata fruit pods are taken, 0.5% sulfuric acid is used for percolation extraction, then alkali liquor is used for adjusting the pH value of the solution to be about 10 for precipitation, precipitation is obtained after filtration, the precipitation is dried, dissolved by 90% ethanol and then added with sulfuric acid solution for precipitation, filtration is carried out, the precipitation is dried, 113.4g of macleaya cordata extract is obtained, and the percentage content of sanguinarine is 40.9% measured by liquid phase.
(2) Extracting herba Leonuri 4kg with 10 times of water for 2 times, mixing the water extracts, and concentrating to about 1.10g/cm3Adding 95% ethanol with equivalent amount, precipitating with ethanol, recovering ethanol, and drying to obtain herba Leonuri extract 365.8g, which has stachydrine hydrochloride of 3.2%.
(3) Mixing the extract of herba Macleayae Cordatae and herba Leonuri extract, adding sodium citrate 110g and sodium carboxymethylcellulose 33g, mixing, packaging, and sterilizing.
Example 2
(1) 7.5kg of macleaya cordata fruit pods are taken, 0.5% sulfuric acid is used for percolation extraction, then the pH value of the solution is adjusted to be about 10 by using alkali liquor for precipitation, precipitation is obtained after filtration, the precipitation is dried, dissolved by 90% ethanol and then added with sulfuric acid solution for precipitation, filtration is carried out, 141.2g of macleaya cordata extract is obtained after the precipitation is dried, and the percentage content of sanguinarine is 41.2% measured by liquid phase.
(2) Extracting herba Leonuri 2.5kg with 10 times of water for 2 times, mixing the water extracts, and concentrating to about 1.10g/cm3Adding equal amount of 95% ethanol, precipitating with ethanol, recovering ethanol, and drying to obtain herba Leonuri extract 230.8g, wherein stachydrine hydrochloride is 3.4% by liquid phase assay.
(3) Mixing the extract of herba Macleayae Cordatae and herba Leonuri extract, adding 142g sodium citrate and 33g sodium carboxymethylcellulose, mixing, packaging, and sterilizing.
Example 3
(1) Taking 9kg of macleaya cordata fruit pods, percolating and extracting the macleaya cordata fruit pods by using 0.5% sulfuric acid, then adjusting the pH value of a solution to be about 10 by using an alkali solution for precipitation, filtering the solution to obtain a precipitate, drying the precipitate, dissolving the precipitate by using 90% ethanol, adding a sulfuric acid solution for precipitation, filtering the precipitate, drying the precipitate to obtain 167.4g of macleaya cordata extract, and measuring the percentage content of sanguinarine in a liquid phase to be 42.8%.
(2) Extracting herba Leonuri 1kg with 10 times of water for 2 times, mixing the water extracts, and concentrating to about 1.10g/cm3Adding 95% ethanol with the same amount, precipitating with ethanol, recovering ethanol, and drying to obtain herba Leonuri extract 92.5g, wherein stachydrine hydrochloride is 3.1% by liquid phase determination.
(3) Mixing the extract of herba Macleayae Cordatae and herba Leonuri extract, adding 168g sodium citrate and 33g sodium carboxymethylcellulose, mixing, packaging, and sterilizing.
Third, detection of therapeutic effect
Experiment for treating mouse endometritis induced by lipopolysaccharide
40 female mice of Kunming line were randomly divided into 5 groups in total, including a blank control group (healthy mice), a positive group (non-medicated group), and a treatment group (composition prepared in application examples 1-3), wherein the uterus injection of Macleaya cordata is prepared into a solution of 0.3g (based on total drug material)/1 ml of water. Mice were anesthetized and then injected 20ul of lipopolysaccharide solution (5mg/ml) into the uterus, with 20ul of normal saline injected into the placebo group (healthy mice). After 24 hours, the uterus of each group of mice is firstly washed by normal saline, then 20ul of normal saline is injected into the uterus of the blank group and the positive group, and 20ul of macleaya cordata uterus injectant is injected into the treatment group. The mice are sacrificed 24 hours after the uterus injection treatment, the uterus tissues are dissected and separated, a part of the tissues are cut and fixed in a neutral formaldehyde solution, dehydrated, transparent and embedded according to a conventional method, 4um paraffin sections are prepared, hematoxylin-eosin (HE) staining is carried out to observe the pathological changes of the uterus tissues, and the scores are carried out. Grading standard: (1) edema: normally 0 point; slightly 1 point; the moderate degree is 2 minutes; severe is 3 points. (2) Inflammatory cell infiltration: 0-1 is 0 min; 2-5 is 1 minute; 2 minutes for 6-10; 11-15 is 3 minutes; 16-20 is 4 minutes; >20 is 5 points. The experimental data and results are shown in table 1 below:
TABLE 1
As can be seen from Table 1, the uterine injectant prepared from the compositions prepared in examples 1-3 was effective in reducing the edema and inflammation level of the uterus of endometritis female mice as compared to the positive control group.
(II) treatment of sow endometritis
(1) The selection of cases requires: yellow or white secretion with fishy smell often flows out below the vulva, or filthy and scab are found near the vulva; further, vaginal examination was performed with a prolapsus appliance, and the uterus and vagina were examined for redness, swelling, congestion, and inflammatory secretion.
(2) 40 patients with endometritis were randomly divided into 4 groups of 10 in a sow farm, and the Chinese medicinal composition prepared in example 2 was diluted to 0.1g (by total drug substance)/1 mL of liquid medicine group, 0.3g (by total drug substance)/1 mL of solution group, 0.5g (by total drug substance)/1 mL of solution group, and oxytetracycline group (0.3g/1mL) positive group, respectively.
(3) Each sow is infused with 20ml of liquid medicine uterus every time for 3 days continuously, the result is observed and recorded on the 5 th day, and obvious peculiar smell secretion flowing out of the vulva is ineffective; the vulva does not flow out or basically does not flow out the peculiar smell secretion, but the phenomena of swelling and congestion of the uterine orifice and the vagina are improved; there were no abnormal secretion outside the vulva and the uterus and vagina recovered to normal and cured, as shown in table 2 below:
TABLE 2
From the experimental data shown in table 2, it is found that the uterine injectant of macleaya cordata and leonurus japonicus, which is prepared in 0.3g (calculated as total drug material)/1 ml and 0.5g (calculated as total drug material)/1 ml, has the same therapeutic effect on endometritis of sow as oxytetracycline, and 0.1g (calculated as total drug material)/1 ml is slightly inferior to oxytetracycline.
(III) treatment of cow endometritis
(1) The selection of cases requires: yellow or white secretion with fishy smell often flows out below the vulva, or filthy and scab are found near the vulva; further, vaginal examination was performed with a prolapsus appliance, and the uterus and vagina were examined for redness, swelling, congestion, and inflammatory secretion.
(2) 40 patients with endometritis were randomly divided into 2 groups of 20 in a dairy farm, and the Chinese medicinal composition prepared in example 2 was diluted to 0.3g (based on total drug material)/1 mL of solution group and oxytetracycline group (0.3g/1mL) positive group.
(3) Each piglet is infused with 30ml of liquid medicine uterus every time for 3 days continuously, the result is observed and recorded on the 5 th day, and obvious peculiar smell secretion flows out from the vulva to be ineffective; the vulva does not flow out or basically does not flow out the peculiar smell secretion, but the phenomena of swelling and congestion of the uterine orifice and the vagina are improved; there were no abnormal secretion outside the vulva and the uterus and vagina recovered to normal as a cure, and the conditions are shown in table 3:
TABLE 3
The experimental data in Table 3 show that the uterus injectant of herba Leonuri in 0.3g (calculated by total drug) per 1ml has slightly better therapeutic effect on cow endometritis than oxytetracycline.
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and is not intended to limit the practice of the invention to these embodiments. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (3)
1. The traditional Chinese medicine composition for treating endometritis of female animals is characterized by comprising the following raw materials in parts by weight: 60-90 parts of macleaya cordata and 10-40 parts of motherwort herb, wherein the macleaya cordata and the motherwort herb are extracted to respectively prepare a macleaya cordata extract and a motherwort herb extract, and the mass percentage content of sanguinarine in the macleaya cordata extract is not lower than 40%; the content of stachydrine hydrochloride in the motherwort herb extract is not less than 3 percent by mass;
the traditional Chinese medicine composition also comprises a pH regulator and a cosolvent, wherein the pH regulator is 1.08-1.65 parts, and the cosolvent is 0.32-0.33 part;
the product form of the traditional Chinese medicine composition is solid, the traditional Chinese medicine composition is prepared into an infusion agent by using water or normal saline when in use, and the pH value of the infusion agent is 5.5-7.0;
the composition is prepared by the following steps:
s1, taking 60-90 parts of macleaya cordata fruit pods, percolating and extracting with a dilute acid solution, then adding an alkali liquor, filtering to obtain a precipitate A, drying the precipitate A, extracting with an alcohol solution, then adding an acid solution to obtain a precipitate B, and drying the precipitate B to obtain a macleaya cordata extract of which the sanguinarine content is not lower than 40% in percentage by mass;
s2, taking 10-40 parts of motherwort, extracting with water, concentrating the water extract, adding an alcohol solution for precipitation, recovering the alcohol solution, and drying to obtain a motherwort extract in which the mass percentage content of stachydrine hydrochloride is not lower than 3%;
s3, mixing the macleaya cordata extract prepared in the step S1 and the motherwort herb extract prepared in the step S2, adding a pH regulator and a cosolvent, and sterilizing to obtain the extract;
the dilute acid solution is dilute sulfuric acid, the alkali liquor is sodium hydroxide solution, and the alcohol solution is ethanol solution;
the pH regulator is sodium citrate, and the cosolvent is sodium carboxymethylcellulose.
2. The Chinese medicinal composition for treating dam endometritis according to claim 1, wherein the macleaya cordata extract is extracted and separated from macleaya cordata fruit pods.
3. The use of the Chinese medicinal composition for treating endometritis in a female animal according to claim 1 in the preparation of a medicament for treating endometritis in a female animal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110458793.1A CN113144006B (en) | 2021-04-27 | 2021-04-27 | Traditional Chinese medicine composition for treating endometritis of female animals and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110458793.1A CN113144006B (en) | 2021-04-27 | 2021-04-27 | Traditional Chinese medicine composition for treating endometritis of female animals and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113144006A CN113144006A (en) | 2021-07-23 |
| CN113144006B true CN113144006B (en) | 2022-04-08 |
Family
ID=76871307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110458793.1A Active CN113144006B (en) | 2021-04-27 | 2021-04-27 | Traditional Chinese medicine composition for treating endometritis of female animals and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113144006B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000145A (en) * | 2010-12-16 | 2011-04-06 | 南京日升昌生物技术有限公司 | Traditional Chinese medicine and western medicine compound infusion liquid for preventing and treating endometritis of dam and preparing method thereof |
| CN103223021A (en) * | 2013-05-15 | 2013-07-31 | 中国农业科学院兰州畜牧与兽药研究所 | Uterine infusion drug for preventing and treating endometritis of dairy cows and sows and preparation method of uterine infusion drug |
| CN103768065A (en) * | 2014-01-06 | 2014-05-07 | 湖南理工学院 | Application of sanguinarine and salt thereof as spermatozoicide |
| CN104524093A (en) * | 2015-01-15 | 2015-04-22 | 河北科技师范学院 | Chinese herb perfusion fluid for treating endometritis of milk cows |
| CN104524506A (en) * | 2014-12-19 | 2015-04-22 | 北京农学院 | Traditional Chinese medicine uterus cleaning perfusion agent for treating livestock endometritis and preparation method thereof |
| CN110507736A (en) * | 2019-06-20 | 2019-11-29 | 安徽牧春堂天然药物研究开发有限公司 | It is a kind of for treating the traditional Chinese medicine infusion solution and preparation method thereof of dam endometritis |
-
2021
- 2021-04-27 CN CN202110458793.1A patent/CN113144006B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000145A (en) * | 2010-12-16 | 2011-04-06 | 南京日升昌生物技术有限公司 | Traditional Chinese medicine and western medicine compound infusion liquid for preventing and treating endometritis of dam and preparing method thereof |
| CN103223021A (en) * | 2013-05-15 | 2013-07-31 | 中国农业科学院兰州畜牧与兽药研究所 | Uterine infusion drug for preventing and treating endometritis of dairy cows and sows and preparation method of uterine infusion drug |
| CN103768065A (en) * | 2014-01-06 | 2014-05-07 | 湖南理工学院 | Application of sanguinarine and salt thereof as spermatozoicide |
| CN104524506A (en) * | 2014-12-19 | 2015-04-22 | 北京农学院 | Traditional Chinese medicine uterus cleaning perfusion agent for treating livestock endometritis and preparation method thereof |
| CN104524093A (en) * | 2015-01-15 | 2015-04-22 | 河北科技师范学院 | Chinese herb perfusion fluid for treating endometritis of milk cows |
| CN110507736A (en) * | 2019-06-20 | 2019-11-29 | 安徽牧春堂天然药物研究开发有限公司 | It is a kind of for treating the traditional Chinese medicine infusion solution and preparation method thereof of dam endometritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113144006A (en) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104288356B (en) | Treat traditional Chinese medicine infusion solution of mastitis for milk cows and preparation method thereof | |
| EA029649B1 (en) | Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof | |
| CN105749149B (en) | A kind of nonirritant conception control gel and preparation method thereof with bacteria resistance function | |
| CN103919931B (en) | A kind of composition of medicine for preventing and treating sheep aftosa and preparation method thereof | |
| CN113144006B (en) | Traditional Chinese medicine composition for treating endometritis of female animals and preparation method and application thereof | |
| CN101310734A (en) | Chinese and western combine compound uterus perfusate for treating cow endometritis | |
| CN112675085A (en) | Itching-relieving and soothing liquid for skin and preparation method thereof | |
| CN116492397B (en) | Preparation for improving cow breeding performance, preparation method thereof and method for improving cow breeding performance | |
| CN110693895A (en) | Pharmaceutical composition for treating hemorrhoids and preparation thereof | |
| CN113350427A (en) | Suppository for treating gynecological inflammation and preparation method thereof | |
| CN101732662B (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method thereof | |
| CN104306909B (en) | Prevent and treat Chinese medicine composition of cattle uterus subinvolution and preparation method thereof | |
| CN113332340A (en) | Plant compound extract and application thereof in preparation of macleaya cordata oral liquid | |
| CN105395527A (en) | A preparing method of a marine-organism wound-protecting film spraying agent | |
| CN110507736B (en) | A Chinese medicinal perfusate for treating endometritis of female animal, and its preparation method | |
| CN103191232B (en) | Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle and preparation and application of composition | |
| CN106265894A (en) | A kind of herbal medicine treating fowl bacterial diarrhoea and its production and use | |
| CN104840581A (en) | Traditional veterinary medicine combination for treating prolonged lochia and delayed estrus of sow and preparation method thereof | |
| CN112472740B (en) | Chinese herbal medicine compound preparation for preventing and treating cow mastitis and application thereof | |
| CN113577023B (en) | Triazamidine suspension injection and preparation method thereof | |
| CN112999283A (en) | Gynecological lotion and preparation method thereof | |
| CN116350737B (en) | Composition for preventing cow fetal membranes from being damaged and preparation method thereof | |
| CN104208194B (en) | Traditional Chinese medicine composition for treating bovine endometritis, preparation method and application thereof | |
| CN112206259B (en) | Traditional Chinese medicine composition for treating vaginitis, traditional Chinese medicine lotion and application | |
| CN108324721B (en) | Pharmaceutical composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |